|Articles|May 18, 2016
CDISC and TransCelerate Announce New Standard for Breast Cancer
CDISC and TransCelerate announce new Therapuetic Area Standard for Breast Cancer, which allows for data to be shared among industry professionals.
Advertisement
CDISC and TransCelerate announce the availability of a new CDISC Therapeutic Area Standard for Breast Cancer. This standard has the ability to streamline the way clinical research is conducted so that data can be shared among clinicians, researchers and regulators worldwide. Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
2
Subcutaneous Saphnelo Shows Positive Phase III Results in Systemic Lupus Erythematosus
3
ACT Brief: Policy Shifts, FDA Inspections, and Tariffs Pose New Challenges for Clinical Trials
4
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
